The institution is rethinking what a museum can be by prioritizing experimentation, artistic production and public engagement ...
For decades, Los Angeles business and political figures have focused their attention on creating a sleek, vibrant downtown. The common thought, as the late Eli Broad suggested, has been, "a great city ...
Zacks Investment Research on MSN
LLY expands cell therapy ambitions with $2.4B Orna Therapeutics deal
Eli Lilly LLY announced that it entered a definitive agreement to acquire the privately held clinical-stage biotech Orna Therapeutics in a deal valued at $2.4 billion. This transaction includes both ...
Zacks Investment Research on MSN
Should you invest in the Vanguard Health Care ETF (VHT)?
Designed to provide broad exposure to the Healthcare - Broad segment of the equity market, the Vanguard Health Care ETF (VHT) is a passively managed exchange traded fund launched on January 26, 2004.
Innovent Biologics has entered into a strategic collaboration with US pharmaceutical giant Eli Lilly and Company to jointly advance novel medicines in oncology and immunology, a deal that reflects the ...
Eli Lilly (LLY) stock acquiring Orna Therapeutics for up to $2.4 billion to develop circular RNA CAR-T therapies for B ...
Stock index futures were deeply in the red on Thursday as investors digested Alphabet’s earnings beat and assessed the latest labor data. Here are the four stocks to watch on the day: Eli Lilly (LLY) ...
Eli Lilly to acquire Orna Therapeutics for up to $2.4B, boosting in vivo CAR-T and circular RNA therapies for autoimmune disease.
MacKenzie Scott was the nation’s top philanthropist in 2025 and ranks third behind Warren Buffett and Bill Gates and Melinda ...
The Michigan State University Board of Trustees officially named its new engineering center and approved several campus ...
The high-powered duo is teaming up to build and equip a $1 billion research facility in California. The pair, both titans of their respective industries, aren't typically seen as compatible businesses ...
Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has now introduced a pill version of its GLP-1 weight loss drug. Eli Lilly's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results